Improving response: microbiome-based approaches to checkpoint inhibitor resistance
Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, explores how a diversified gut microbiome could improve the treatment of cancer. … Read More
Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, explores how a diversified gut microbiome could improve the treatment of cancer. … Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative therapies showed the way to more effective cancer treatments. Elsewhere, how can… Read More
News round-up for 2 – 6 February by Bruno Quinney, Content Team at DDW. This week in DDW, innovative therapies could pave the way to more effective cancer treatments. Elsewhere, how can brain function be improved in Alzheimer’s patients? The top stories: Immunotherapy before surgery… Read More
Administering immunotherapy to melanoma patients before surgery could shrink tumours and improve quality of life. New research, published in Nature Cancer, shows that 71% of desmoplastic melanoma patients who received the immunotherapy drug pembrolizumab before surgery had no detectable cancer remaining at the time of surgery. Administering… Read More
The US Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a registration Phase III trial of iSCIB1+ Immunobody in advanced melanoma. The application, submitted by biotechnology company Scancell Holdings, has been cleared with progression free survival as the agreed surrogate endpoint. Scancell has completed the 140-patient… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an innovative therapy showed encouraging results in tackling melanoma. Elsewhere, why is… Read More
News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW. This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology. The top stories: Combination therapy could slash melanoma mortality… Read More
Merck and Moderna have announced encouraging five-year data for a therapy treating patients with high-risk melanoma. The Phase IIb trial of intismeran autogene, an investigational mRNA-based individualised neoantigen therapy (INT), reduced the risk of high-risk melanoma recurrence or death by 49% when combined with Keytruda (pembrolizumab). The combination… Read More
Aulos Bioscience has dosed its first patient with a combination of AU-007, the anti-PD-1 antibody nivolumab and low-dose, subcutaneous aldesleukin in a Phase II expansion cohort focused on second-line treatment of melanoma. The new cohort forms part of the company’s Phase I/II clinical trial of AU-007… Read More
Eikon Therapeutics has announced the initial closing of a $350.7 million Series D financing, led by existing investors. Since its founding in 2019, the company has privately raised over $1.1 billion. “Eikon has made remarkable progress in advancing a pivotal-stage clinical pipeline and early-stage development programme… Read More
UK researchers have designed a new genetic therapy that could alleviate debilitating giant moles in a rare skin condition. The treatment could be used to reverse moles, and therefore prevent cancer. It could also potentially reverse other types of at-risk moles as an alternative to surgery. Read More
Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. The combination therapy was also shown to reduce the risk of distant metastasis or… Read More
A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. As reported by The Guardian, the global Phase III clinical trial is being led by University College London Hospitals NHS Foundation Trust (UCLH) and… Read More
News round-up for 26 Feb – 1 March by DDW Digital Content Editor Diana Spencer. The news highlights this week all focus on regulatory decisions, both positive and negative. The first therapy was approved for allergic reactions to food, a drug for scleroderma secured Fast Track Designation, and… Read More
The US Food and Drug Administration has approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of metastatic, unresectable melanoma. It is approved for use in adults that have previously been treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a… Read More
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bristol Myers Squibb’s advanced melanoma drug Opdualag (nivolumab-relatlimab) for patients from the age of 12. Opdualag was authorised through Project Orbis, a global partnership between the MHRA, the Therapeutics Goods Administration in Australia, Health Canada,… Read More